Director, Oncology National Accounts at Acadia Pharmaceuticals

Parsippany, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceuticals, OncologyIndustries

Requirements

Bachelor’s degree required; MBA or other advanced degree preferred
Minimum 10 years in pharma or specialty sales position with a minimum of 5 years of documented success with national / regional oncology organizations and networks required
Deep knowledge and proven success in oncology sales and national / regional systems
Thorough understanding of IDN systems, medical policies, pathway and protocols, and buy and bill process required
Documented access to appropriate stakeholders in targeted accounts preferred
Strong understanding of health system decision making

Responsibilities

Identify and create action plans for national oncology organizations to ensure barriers are removed to achieve rapid uptake of the product
Execute business plans, establish call points and action sales calls with appropriate stakeholders to map organizations interests and hierarchy
Lead forementioned organizations/institute communications pathways, protocols and education regarding the product to all customer stakeholders
Integrate as critical part of pull-through with local field teams creating joint responsibilities for achieving objectives
Clearly communicate ongoing success, opportunities and identify new, unique and profitable business opportunities
Ensure collaboration and partnership with field leadership, market access, marketing and operations to ensure best in class launch

Skills

National Account Management

Oncology Sales

Pharmaceutical Sales

Uro-Oncology

Gene Therapy

Customer Relationship Management

Account Pull-Through

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free